Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20575402 | 0.89 | CHRM5 (0.33) | CHRM5 | |
| SCHEMBL20575351 | 0.89 | CHRM5 (0.36) | CHRM5 | |
| SCHEMBL20575652 | 0.85 | WDR5 (0.34) | CHRM5 | |
| SCHEMBL20574748 | 0.84 | CHRM5 (0.35) | CHRM5 | |
| SCHEMBL20574818 | 0.82 | SLC6A2 (0.32) | CHRM5 | |
| SCHEMBL20575352 | 0.81 | CHRM5 (0.33) | CHRM5 | |
| SCHEMBL20574749 | 0.79 | CHRM5 (0.33) | CHRM5 | |
| SCHEMBL20575424 | 0.79 | CHRM5 (0.34) | CHRM5 | |
| SCHEMBL20575419 | 0.79 | CHRM5 (0.33) | CHRM5 | |
| SCHEMBL20575460 | 0.79 | CHRM5 (0.34) | CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180346487-A1 | Fused Imidazole Derivatives as TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2018-12-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180346487-A1 | Fused Imidazole Derivatives as TGF-Beta Inhibitors | TGFBR1, TGFBR2, SMAD3 | CHRM5 1140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.